A5028180894- Antibiotic Use and Resistance
- Antibiotics Pharmacokinetics and Efficacy
- Antibiotic Resistance in Bacteria
- Bacterial Identification and Susceptibility Testing
- Pneumonia and Respiratory Infections
- Antifungal resistance and susceptibility
- Fungal Infections and Studies
- Respiratory Support and Mechanisms
- Infective Endocarditis Diagnosis and Management
- Streptococcal Infections and Treatments
- Renal cell carcinoma treatment
- Nail Diseases and Treatments
- Diphtheria, Corynebacterium, and Tetanus
- Pharmacogenetics and Drug Metabolism
- Renal and related cancers
- Pharmacological Effects and Toxicity Studies
- Drug Transport and Resistance Mechanisms
- Yersinia bacterium, plague, ectoparasites research
- Cancer Genomics and Diagnostics
- COVID-19 Clinical Research Studies
- Long-Term Effects of COVID-19
- Leprosy Research and Treatment
- Pharmaceutical studies and practices
- Antimicrobial Resistance in Staphylococcus
Indiana University Health
2008-2023
Indiana University – Purdue University Indianapolis
2016-2023
Indiana University School of Medicine
2023
Indiana University Hospital
2017
HealthPartners
2008
University of Wisconsin–Madison
2006-2008
Ceftazidime-avibactam is a novel cephalosporin-beta-lactamase inhibitor combination that active against many carbapenem-resistant Enterobacteriaceae (CRE). We describe retrospective chart review for 60 patients who received ceftazidime-avibactam CRE infection. In-hospital mortality was 32%, 53% of had microbiological cure, and 65% clinical success. In this severely ill population with infections, an appropriate option.
Abstract Background Multidrug-resistant Pseudomonas aeruginosa infections remain common in hospitals worldwide. We investigated the outcomes associated with use of ceftolozane-tazobactam for treatment these infections. Methods Data were collected retrospectively from 20 across United States about adults who received multidrug-resistant P any source at least 24 hours. The primary outcome was a composite 30-day and inpatient mortality, secondary clinical success microbiological cure....
We evaluated the performance and time to result for pathogen identification (ID) antimicrobial susceptibility testing (AST) of Accelerate Pheno™ system (AXDX) compared with standard care (SOC) methods. also assessed hypothetical improvement in antibiotic utilization if AXDX had been implemented.Clinical samples from patients monomicrobial Gram-negative bacteraemia were tested between SOC methods VERIGENE® Bruker MALDI Biotyper® systems ID VITEK® 2 AST. Additionally, charts reviewed calculate...
Abstract Background Real-world data assessing outcomes of immunocompromised patients treated with ceftolozane/tazobactam (C/T) are limited. This study evaluated treatment and clinical receiving C/T for multidrug-resistant (MDR) Pseudomonas aeruginosa. Methods was a 14-center retrospective cohort adult inpatients ≥24 hours MDR P. aeruginosa infections. Patients were defined as if they had history previous solid organ transplant (SOT), disease that increased susceptibility to infection, or...
This study was conducted to assess the utility of T2Candida panel across an academic health center and identify potential areas for diagnostic optimization. A retrospective chart review on patients with a mycolytic/fungal (myco/f lytic) blood culture collected simultaneously during hospitalizations from February 2017 March 2018.
Antibiotic therapy for uncomplicated Enterobacterales bacteremia from a urinary source has traditionally consisted of fluoroquinolones (FQs) and sulfamethoxazole-trimethoprim (SXT). However, adverse events associated with FQs emerging antimicrobial resistance have led to alternative agents, specifically oral Β-lactams (OBLs), being utilized despite concern subtherapeutic serum concentrations related their low relative bioavailability.To compare efficacy antibiotic therapies bioavailability...
Ceftolozane-tazobactam (TOL-TAZ) is a novel cephalosporin/β-lactamase inhibitor combination with potent activity against Pseudomonas aeruginosa, including MDRPA. TOL-TAZ use for MDRPA infections has not been well-studied. We conducted retrospective study to describe outcomes of patients treated MDR aeruginosa at 3 academic medical centers. Patients were age ≥ 18 years who had isolated in culture and received least 24 hours. The primary 30-day in-hospital mortality. Secondary microbiological...
Abstract Background The SARS-CoV-2 pandemic has caused over 400,000 deaths worldwide thus far, and poses therapeutic challenges for millions of patients. There is currently no treatment infection approved by the United States Food Drug Administration. Multiple agents have been used off-label to treat based on small observational cohorts in vitro data. Here we present experience a large academic medical center treating infection. Methods We performed retrospective cohort study patients...
This study’s aim was to compare pathogen identification (ID) and antimicrobial susceptibility testing (AST) result turnaround times of the Accelerate Pheno™ system (AXDX) against current standard methods (SOC). Secondarily, we assessed whether its implementation for positive blood cultures (PBC) with monomicrobial Gram-negative bacilli could provide theoretical improvement in time active optimal antibiotic therapy. Over 3 months, PBC from 114 patients, including 29 pediatric were identified...